VERTEX PHARMACEUTICALS INC / MA (VRTX) — financial distillation
Annual history (10-K)
Quarterly history (10-Q)
Two headline lines are shown to start. Click any item in a legend to add or remove it — every figure on the chart is one the table below also carries, for the period it names.
In brief, from the full filed history
- Revenue grew from $175.5M (period ending 2008-12-31) to $12.00B (period ending 2025-12-31) — a 28.2% annual pace across 17 year(s) of filed history.
- Net margin turned from a loss (-630.3%) to a 32.9% margin over that same span.
- Across 53 tracked quarters, the strongest was $3.33B (quarter ending 2026-06-30) and the weakest was $19.1M (quarter ending 2009-06-30).
Annual — most recent 10-K
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $12.00B | 2025-12-31 | 10-K | 0000875320-26-000056 |
| Operating income | $4.17B | 2025-12-31 | 10-K | 0000875320-26-000056 |
| Net income | $3.95B | 2025-12-31 | 10-K | 0000875320-26-000056 |
| Diluted EPS | $15.32 | 2025-12-31 | 10-K | 0000875320-26-000056 |
| Total assets | $25.64B | 2025-12-31 | 10-K | 0000875320-26-000056 |
| Total liabilities | $6.98B | 2025-12-31 | 10-K | 0000875320-26-000056 |
| Cash & equivalents | $5.08B | 2025-12-31 | 10-K | 0000875320-26-000056 |
| Operating cash flow | $3.63B | 2025-12-31 | 10-K | 0000875320-26-000056 |
Quarterly — most recent 10-Q
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $3.33B | 2026-06-30 | 10-Q | 0000875320-26-000259 |
| Operating income | $1.25B | 2026-06-30 | 10-Q | 0000875320-26-000259 |
| Net income | $1.10B | 2026-06-30 | 10-Q | 0000875320-26-000259 |
| Diluted EPS | $4.31 | 2026-06-30 | 10-Q | 0000875320-26-000259 |
| Total assets | $27.42B | 2026-06-30 | 10-Q | 0000875320-26-000259 |
| Total liabilities | $7.18B | 2026-06-30 | 10-Q | 0000875320-26-000259 |
| Cash & equivalents | $6.14B | 2026-06-30 | 10-Q | 0000875320-26-000259 |
| Operating cash flow | $1.43B | 2026-03-31 | 10-Q | 0000875320-26-000173 |
Reading
The figures above are taken directly from filings with the U.S. Securities and Exchange Commission. The reading below was generated by a local language model from only those figures; it introduces no numbers of its own. It is not investment advice.
Vertex Pharmaceuticals Inc./MA’s business scale is substantial, with a revenue of $12.00B in the most recent annual period, reflecting a robust growth trajectory. Over the past 17 years, as per the SEC filings, the company has demonstrated an impressive revenue expansion at a compound annual rate of 28.2%. This growth is evident from its humble beginnings of $175.5M in 2008 to the recent $12.00B mark.
The company’s financial health has also significantly improved, transitioning from substantial net losses in earlier years to a positive net income of $3.95B in the latest annual period. This transformation is underscored by an increase in net margin from a staggering loss of -630.3% to a healthy 32.9%. The company’s operating cash flow further supports this financial strength, with consistent generation of over $3.63B annually.
In the most recent quarterly filing, Vertex reported revenue of $3.33B and net income of $1.10B, marking a continuation of its growth trend. However, investors should monitor the company’s ability to sustain this momentum amidst potential market dynamics or regulatory changes that could impact its pharmaceutical business. The next filing will be crucial in assessing Vertex’s capacity to maintain its current financial performance and growth trajectory.
Source: SEC EDGAR company facts for CIK 0000875320 · filings index